Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT04738188 Recruiting - Clinical trials for Hepatocellular Carcinoma

Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

Start date: March 18, 2020
Phase: N/A
Study type: Interventional

This is a multicenter, randomized, parallel controlled study to determine the efficacy and safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma beyond University of California, San Francisco (UCSF) criteria.

NCT ID: NCT04728321 Completed - Clinical trials for Hepatocellular Carcinoma

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Start date: January 27, 2021
Phase: Phase 2
Study type: Interventional

An open-label multi-center phase II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 alone or in combination with lenvatinib in patients with advanced hepatocellular carcinoma.

NCT ID: NCT04727307 Recruiting - Clinical trials for Hepatocellular Carcinoma

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial

AB-LATE02
Start date: January 26, 2021
Phase: Phase 2
Study type: Interventional

Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC. In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a metastatic mechanism encourages exploring adjuvant/neoadjuvant strategies targeting tumor growth and metastatic escape in the context of percutaneous thermal ablation for small HCC. Local ablation of HCC is therefore an "ideal" setting for testing atezolizumab + bevacizumab in combination with ablation, with the aim of reducing the risk of recurrence.

NCT ID: NCT04724226 Recruiting - Clinical trials for Hepatocellular Carcinoma

Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma

C-couple
Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cryoablation combined with pd-1 antibody immunotherapy (Camrelizumab) and anti-angiogenesis therapy (Apatinib) in patients with advanced hepatocellular carcinoma (HCC).

NCT ID: NCT04722120 Completed - Clinical trials for Hepatocellular Carcinoma

Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC

Start date: June 1, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the image quality and clinical feasibility of double low-dose liver computed tomography using a deep-learning-based iodine contrast boosting algorithm in participants at high risk for hepatocellular carcinoma.

NCT ID: NCT04721470 Completed - Clinical trials for Hepatocellular Carcinoma

Combined Therapy for Hepatocellular Carcinoma >3-<5 cm

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only TACE or MWA for treatment of hepatocellular carcinoma (HCC) >3-<5 cm.

NCT ID: NCT04720716 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Start date: February 7, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, controlled, multicenter Phase III study to evaluate the effectiveness and safety of IBI310 combined with sintilimab and sorafenib in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have had progressive disease after surgical resection or local treatment.

NCT ID: NCT04720430 Completed - Clinical trials for Hepatocellular Carcinoma

Blood Sample Collection for Experimental Blood Test to Track Liver Cancer

Start date: December 3, 2019
Phase:
Study type: Observational

This study investigates if an experimental blood test can help predict how well cancer will remain under control with treatment. Ther experimental blood test involves measuring mircoRNAs. MicroRNAs are small molecules which help regulate how genes are expressed. This information may help researchers guide treatment for other patients in the future.

NCT ID: NCT04715321 Recruiting - Clinical trials for Hepatocellular Carcinoma

CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma

Start date: February 15, 2013
Phase:
Study type: Observational

Distinct vascular patterns (ECTC or Non-ECTC) of tumors plays an important role in tumor migration, metastasis and drug resistant in hepatocellular carcinoma (HCC). However, there is no non-invasive method to predict vascular pattern in clinical. In the present study, we prospectively assess CT perfusion parameters for evaluation of the vascular pattern in HCC.

NCT ID: NCT04712643 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Start date: March 12, 2021
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.